



# CALIFORNIA NEUROLOGY SOCIETY

## “CNS Fall Conference 2023”

November 2 - 5, 2023

### Planner/Faculty Disclosure Statement

Planner Name	Relevant Financial Relationship	Company	COI?	Explain how Resolved
<b>CME CONSULTANTS' REVIEWERS</b>				
William Choctaw, MD, JD	None	N/A	N/A	N/A
Harold D. Damuth, Jr., MD	None	N/A	N/A	N/A
Lester Holstein, MD	None	N/A	N/A	N/A
Michael J. Marchiano, MD	None	N/A	N/A	N/A
<b>CME CONSULTANTS' STAFF</b>				
Nancy Williams	None	N/A	N/A	N/A
Priscilla Graham	None	N/A	N/A	N/A
<b>CNS PLANNERS</b>				
Virginia Ho	None	N/A	N/A	N/A
Stella Legarda MD	None	N/A	N/A	N/A
Johanna Rosenthal, MD	None	N/A	N/A	N/A
George Sarka, MD, DrPH, MPH	None	N/A	N/A	N/A
Robert Weinmann MD	None	N/A	N/A	N/A
Robyn Young MD	None	N/A	N/A	N/A
<b>FACULTY</b>				
Jeff M. Bronstein, MD, PhD	None	N/A	N/A	N/A
Ryan M. Casserly, MD	None	N/A	N/A	N/A
Steve Cattolica	None	N/A	N/A	N/A
Rochelle Frank, MD, FAAN	None	N/A	N/A	N/A
Neeta Garg, MD	None	N/A	N/A	N/A
Steven J. Holtz, MD, FAAN	None	N/A	N/A	N/A
Jeffrey G. Klingman, MD	None	N/A	N/A	N/A
Robert C. Knowlton, MD, MSPH	None	N/A	N/A	N/A
Stella Legarda, MD	None	N/A	N/A	N/A
Kenneth K. Leung, MD	Advisory Board	Amylyx	Yes	*Peer review.
Christopher B. Lock, MD	Speakers Bureau	Bristol Myers Squibb; Horizon Therapeutics	Yes	*Peer review.
Xenos Mason, MD	Consultant, Travel Fees, and Speakerships	Abbott Labs; Boston Scientific	Yes	*Peer review.
Armen Moughamian, MD, PhD	Advisor; Consultant	Eisai; Eli Lilly	Yes	*Peer review.
	Consultant	Biogen; Genentech	No	Ended 3/2022 and 9/2022
	Consultant; Speaker	Corium	Yes	*Peer review.
	Research	Biogen; Eli Lilly	Yes	*Peer review.

Alejandro Rabinstein, MD	Advisory Board	Astra Zeneca; Chiesi Group (ends 12/2023; Shiongi)	Yes	*Peer review.
	Member, Clinical Events Committee for trials	Boston Scientific		
Johanna Rosenthal, MD	None	N/A	N/A	N/A
George Sarka, MD, DrPH, MPH	None	N/A	N/A	N/A
Elyse Singer, MD	None	N/A	N/A	N/A
Danielle Thordarson, MD	None	N/A	N/A	N/A
Robert Weinmann, MD	None	N/A	N/A	N/A

\*Presentation materials have been peer reviewed and found to be fair, balanced, evidence-based, and free from commercial bias.

**COMMERCIAL SUPPORT STATEMENT:**

There is no commercial support for this activity.